# HPN328-4001 (NCT04471727)

> A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

No report yet. It can be ordered.

- Drugs tested: gocatamig (MK-6070); gocatamig (MK-6070) plus atezolizumab; gocatamig (MK-6070) plus ifinatamab deruxtecan
- Indication: advanced DLL3-expressing small-cell lung cancer and neuroendocrine carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04471727
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Conditions: Small-Cell Lung Cancer; Neuroendocrine Carcinoma
- Interventions: Gocatamig; Atezolizumab; Ifinatamab Deruxtecan (I-DXd)
- Enrollment: 232
- Primary outcome: Percentage of participants who experience an adverse event
- Primary outcome: Percentage of participants who discontinue due to an adverse event
- Primary outcome: Number of participants with dose limiting toxicity (DLT) following treatment with HPN328 as monotherapy or in combination with atezolizumab or I-DXd
- Primary outcome: Maximum concentration (Cmax) of Gocatamig
- Primary outcome: Cmax of Atezolizumab
- Primary outcome: Cmax of I-DXd
- Primary outcome: Time to maximum concentration (Tmax) of Gocatamig
- Primary outcome: Tmax of atezolizumab
- Primary outcome: Tmax of I-DXd
- Primary outcome: Area under the concentration-time curve over the dosing interval t (AUCt) of Gocatamig
- Primary outcome: AUCt of atezolizumab
- Primary outcome: AUCt of I-DXd
- Primary outcome: Area under the concentration-time curve extrapolated to infinity (AUCinf) of Gocatamig
- Primary outcome: AUCinf of atezolizumab
- Primary outcome: AUCinf of I-DXd
- Primary outcome: Terminal half-life (t1/2) of Gocatamig
- Primary outcome: t1/2 of atezolizumab
- Primary outcome: t1/2 of I-DXd
- Primary outcome: Single dose clearance (CL) of Gocatamig
- Primary outcome: CL of atezolizumab
- Primary outcome: CL of I-DXd
- Primary outcome: Steady state maximum concentration (Cmax,ss) of Gocatamig
- Primary outcome: Cmax,ss of atezolizumab
- Primary outcome: Cmax,ss of I-DXd
- Primary outcome: Steady state Ctrough (Ctrough,ss) of Gocatamig
- Primary outcome: Ctrough,ss of atezolizumab
- Primary outcome: Ctrough,ss of I-DXd
- Primary outcome: Steady state time to maximum concentration (Tmax,ss) of Gocatamig
- Primary outcome: Tmax,ss of atezolizumab
- Primary outcome: Tmax,ss of I-DXd
- Primary outcome: Area under the steady state concentration-time curve over dosing interval t (AUCt,ss) of Gocatamig
- Primary outcome: AUCt,ss of atezolizumab
- Primary outcome: AUCt,ss of I-DXd
- Primary outcome: Steady state t1/2 (t1/2,ss) of Gocatamig
- Primary outcome: t1/2,ss of Gocatamig with atezolizumab
- Primary outcome: t1/2,ss of IDXd
- Primary outcome: Steady state CL (CL,ss) of Gocatamig
- Primary outcome: CL,ss of Gocatamig with atezolizumab
- Primary outcome: CL,ss of I-DXd
- Primary outcome: Steady state volume of distribution (V,ss) of Gocatamig
- Primary outcome: V,ss of atezolizumab
- Primary outcome: V,ss of I-DXd
- Primary outcome: Steady state accumulation ratio (AC) of Gocatamig
- Primary outcome: AC of atezolizumab
- Primary outcome: AC of I-DXd

## Some of the questions raised in the 9 indexed sources

_Automated from all 9 indexed sources (Dec 2021 – Jun 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether adding ifinatamab deruxtecan or atezolizumab to MK-6070 offers more than MK-6070 alone in SCLC
- Whether MK-6070 has activity in neuroendocrine prostate cancer and other extrapulmonary neuroendocrine carcinomas
- Whether DLL3 expression should be required to select patients for MK-6070

## Indexed commentary on HPN328-4001 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X

## Order

Focused first edition, $750. Buy the first edition with create_order on https://mcp.erudio.com/mcp (product "first_edition", report "NCT04471727", the buyer's work email and organization), or POST https://www.erudio.com/api/orders with the same fields. It returns a Stripe checkout_url for your person to pay by card; a first edition has no agent-wallet payment. The person can also order on https://www.erudio.com/trials/hpn328-4001-nct04471727. We build the first edition within 24 hours of payment and email it to you once it passes our checks and review. If your report can't be delivered, we'll contact you and refund it in full.

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04471727", "email": "<work email>"}; the inbox owner confirms by the emailed link.
